DDInter469 DDInter1676
Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Dalfopristin {u} (Compound) binds {v} (Gene) CYP3A4
Dalfopristin {u} (Compound) is included by {v} (Pharmacologic Class) Streptogramins
Dalfopristin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Dalfopristin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolic acid
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Dalfopristin {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Dalfopristin {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Dalfopristin (Compound) binds CYP3A4 (Gene)
Dalfopristin (Compound) is included by Streptogramins (Pharmacologic Class)
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Dalfopristin may lead to a major life threatening interaction when taken with Encorafenib
Dalfopristin may lead to a major life threatening interaction when taken with Tamoxifen